Chemical and Pharmaceutical Bulletin p. 1486 - 1493 (1992)
Update date:2022-08-04
Topics:
Yamanaka
Suda
Kabasawa
Kawamura
Ogawa
Sawada
Ohhara
Structural modification of the cardiotonic agent, loprinone (E-1020, 1), suggested by data that it has a less positive chronotropic effect than milrinone (15), led us to find novel bradycardic agents that were structurally different from homoveratryl amine derivatives. Alkyl-oxy, -thio, and -amino derivatives at the 2-position of the pyridine ring of 1 produced bradycardic activity without a significant effect on blood pressure and myocardial contractility. Aryloxy analogues also decreased beart rate, and members with an electron-withdrawing group at the ortho position of the phenyl ring showed higher activity. Replacement of the imidazo[1,2-a]pyridine with pyridine resulted in diminished activity. The mechanism of bradycardic activity of these compounds seems to be direct action on the sinus node.
View MoreChengdu Pukang Biotechnology Co., Ltd
Contact:+86-28-82550498
Address:No. 558 Rulin Road,Xinjin county,Chengdu city, China
Shanghai ZaiQi Bio-Tech Co., Ltd.,
Contact:+86-21-5482 4098
Address:Bldg. No.7, No.201 MinYi Rd,Songjiang CaoHeJing High-Tech Park Shanghai 201516 P,R,China
Jiangsu Taihu New Materials Holding Co., Ltd
Contact:+86-519-86160108
Address:Xueyan Town, Changzhou City, Jiangsu Province, 213169, China
WENZHOU M&C FOREIGN TRADE CO.,LTD.
Contact:+86-577-88862917
Address:No.8 Liming West Road,Wenzhou,zhejiang,China
Jiangsu Zenji Pharmaceuticals LTD
Contact:+86-025-83172562; +1-224-888-1133(USA)
Address:No.5 Xinmofan Road
Doi:10.1021/ol401276b
(2013)Doi:10.1080/00304948.2013.786587
(2013)Doi:10.1016/S0022-1139(98)00310-8
(1999)Doi:10.1021/ja00050a030
(1992)Doi:10.1002/anie.201209109
()Doi:10.1016/S0040-4020(01)88306-X
(1992)